N-[3-(4-ethyl-1,4-diazepane-1-carbonyl)phenyl]naphthalene-2-sulfonamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-[3-(4-ethyl-1,4-diazepane-1-carbonyl)phenyl]naphthalene-2-sulfonamide
• 化学式: C₂₄H₂₇N₃O₃S
• 分子量: 437.6
• InChiKey: SDXVJCAJFZFERD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  78.1
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Pyrazine Derivatives Useful as Adenosine Receptor Antagonists
  申请人：Vidal Juan Bernat

  公开号：US20090042891A1

  公开（公告）日：2009-02-12

  The present disclosure relates to a compound of formula (I) wherein: A is an optionally substituted monocyclic or polycyclic aryl or heteroaryl group; B is an optionally substituted monocyclic nitrogen-containing heteroaryl group; and either a) R 1 and R 2 are chosen from a hydrogen atom and specified substituents, or b) R 2 , R 1 and the —NH— group to which R 1 is attached, form a moiety chosen from the moiety of formulae (IIa) and (IIb): or a pharmaceutically acceptable salt thereof, or a N-oxide thereof. The present disclosure also relates to a method for treating a subject afflicted with a pathological condition or disease susceptible to amelioration by antagonism of the A 2B adenosine receptor.

  本公开涉及一种式（I）的化合物，其中：A是可选取的取代的单环或多环芳基或杂芳基基团；B是可选取的取代的单环含氮杂芳基基团；并且要么a）R1和R2选择自氢原子和指定的取代基，要么b）R2、R1和R1附着的—NH—基团形成式（IIa）和（IIb）的基团：或其药学上可接受的盐或其N-氧化物。本公开还涉及一种治疗患有病理状况或疾病，易于通过拮抗A2B腺苷受体而改善的受试者的方法。
• PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS
  申请人：Vidal Juan Bernat

  公开号：US20100273757A1

  公开（公告）日：2010-10-28

  The present invention provides a compound of formula (I) wherein: A represents an optionally substituted monocyclic or polycyclic aryl or heteroaryl group B represents an optionally substituted monocyclic nitrogen-containing heteroaryl group; and either a) R 1 and R 2 represent hydrogen or specified substituents, or b) R 2 , R 1 and the —NH— group to which R 1 is attached, form a moiety selected from the moiety of formulae (IIa) and (IIb): (IIa) These compounds are useful as antagonists of the A2B receptor, for instance in the treatment of asthma.

  本发明提供了一种式为（I）的化合物，其中：A代表可选取代的单环或多环芳基或杂芳基基团；B代表可选取代的单环含氮杂芳基基团；并且要么a）R1和R2代表氢或指定的取代基，要么b）R2，R1和R1连接的—NH—基团形成从式（IIa）和（IIb）中选择的基团：（IIa）这些化合物可用作A2B受体拮抗剂，例如在哮喘治疗中。
• US7790728B2
  申请人：——

  公开号：US7790728B2

  公开（公告）日：2010-09-07
• [EN] PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE PYRAZINE UTILES EN TANT QU'ANTAGONISTES DE RECEPTEUR D'ADENOSINE
  申请人：ALMIRALL PRODESFARMA SA

  公开号：WO2007017096A1

  公开（公告）日：2007-02-15

  [EN] The present invention provides a compound of formula (I) wherein: A represents an optionally substituted monocyclic or polycyclic aryl or heteroaryl group B represents an optionally substituted monocyclic nitrogen-containing heteroaryl group ; and either a) R¹ and R² represent hydrogen or specified substituents, or b) R², R¹ and the -NH- group to which R¹ is attached, form a moiety selected from the moiety of formulae (IIa) and (IIb): (IIa) These compounds are useful as antagonists of the A2B receptor, for instance in the treatment of asthma.
  [FR] La présente invention propose un composé de formule (I) dans laquelle : A représente un groupe aryle ou hétéroaryle monocyclique ou polycyclique facultativement substitué, B représente un groupe hétéroaryle contenant de l'azote facultativement substitué ; et a) R¹ et R² représentent un hydrogène ou des substituants spécifiés, ou b) R², R¹ et le groupe -NH- auquel R¹ est lié, forment un groupe choisi parmi les groupes de formule (IIa) et (IIb) : (IIa) Ces composés sont utiles en tant qu'antagonistes du récepteur A2B, par exemple dans le traitement de l'asthme.
• [EN] FUNCTION OF CHEMOKINE RECEPTOR CCR8 IN MELANOMA METASTASIS<br/>[FR] FONCTION DU RÉCEPTEUR DE CHIMIOKINE CCR8 DANS DES MÉTASTASES DE MÉLANOME
  申请人：ICAHN SCHOOL MED MOUNT SINAI

  公开号：WO2013131010A2

  公开（公告）日：2013-09-06

  This invention provides a method of treating a subject who has, or has been treated for, a solid tumor which comprises administering to the subject an antagonist of CCR8 receptors on the surface of tumor cells present in the solid tumor in an amount effective to reduce binding of CCL1 to the CCR8 receptors so as to thereby treat the subject. This invention also provides a method of reducing, or reducing the likelihood of, metastases in a subject who has, or has been treated for, a solid tumor which comprises administering to the subject an antagonist of CCR8 receptors on the surface of tumor cells present in the solid tumor in an amount effective to reduce binding of CCL1 to the CCR8 receptors so as to thereby reduce, or reduce the likelihood of, metastases in the subject.